FibroBiologics Announces Pricing of $3 Million Public Offering FibroBiologics (NASDAQ: FBLG) priced a best-efforts public offering of 2,272,728 common shares and warrants at a combined price of $1.32 each, expected to raise approximately $3.0 million gross, before fees. Warrants cover up to 2,272,728 shares at a $1.32 exercise price.The offering closing is expected on or about April 2, 2026, subject to customary conditions and stockholder approval for warrant exercises; potential additional gross proceeds from full warrant exercise equal approximately $3.0 million. Net proceeds are for working capital and general corporate purposes.

#FBLG FibroBiologics Announces Pricing of $3 Million Public Offering

www.stocktitan.net/news/FBLG/fibro-biologic...

First batch of foot-ulcer therapy made for planned human trial Made under FDA good manufacturing practices, CYWC628 now heads to safety testing. FibroBiologics plans a Phase 1/2 trial in H1 2026.

#FBLG FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

www.stocktitan.net/news/FBLG/fibro-biologic...

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement FibroBiologics (Nasdaq: FBLG) announced a 1-for-20 reverse stock split expected to take effect at 12:01 a.m. ET on March 30, 2026, to regain compliance with Nasdaq's minimum bid price requirement.Post-split outstanding shares will decrease from 70,256,883 to approximately 3,512,845, fractional shares rounded up, and trading will continue under the ticker FBLG.

#FBLG FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement

www.stocktitan.net/news/FBLG/fibro-biologic...

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using proprietary fibroblast

#FBLG FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

www.stocktitan.net/news/FBLG/fibro-biologic...

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and

#FBLG FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

www.stocktitan.net/news/FBLG/fibro-biologic...

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis FibroBiologics (Nasdaq: FBLG) announced issuance of U.S. Patent No. 12,544,407 B2, dated February 10, 2026, covering fibroblast cell therapy for osteoporosis. The patent claims systemic and local administration, modified/dedifferentiated fibroblasts (OCT4, NANOG, SOX2), recombinant CXCR4/hTERT, marker-selected cells, and combination use with anti-inflammatory agents.This issuance strengthens the company’s intellectual property in regenerative medicine and bone disorders and supports its strategy to develop proprietary fibroblast therapies addressing osteoporosis and related bone diseases.

#FBLG FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

www.stocktitan.net/news/FBLG/fibro-biologic...

#FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 1Q26 buff.ly/0d9ga3Z

FibroBiologics CEO Issues Letter to Shareholders FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and

#FBLG FibroBiologics CEO Issues Letter to Shareholders

www.stocktitan.net/news/FBLG/fibro-biologic...

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis FibroBiologics (Nasdaq: FBLG) filed a Phase 1/2 IND application with the U.S. FDA on Dec 31, 2025 to seek clearance to start first-in-human trials of CYPS317, an allogeneic fibroblast spheroid therapy for moderate to severe psoriasis.The submission includes preclinical pharmacology, safety, and manufacturing data; animal studies showed a single dose of CYPS317 matched or exceeded multiple doses of anti-IL-23 antibodies and reduced disease recurrence. The company says it aims to advance clinical development and pursue IND clearance for all four product candidates in 2026.

#FBLG FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

www.stocktitan.net/news/FBLG/fibro-biologic...

Trade Alerts, Monday December 15, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Mon Dec 15th - #SMX #PCLA #ORKT #MIGI #LEXX #GOVX #GLXG #FBLG #EPSM #SNSE #MNTS #IRBT #ATOS #ALBT - More: crystalequityresearch.com/trade-alerts... - #smallcap

FibroBiologics Announces Payoff of Outstanding Debt FibroBiologics (Nasdaq: FBLG) announced it has paid in full the convertible promissory notes issued to Yorkville under the Standby Equity Purchase Agreement (SEPA), eliminating those notes and any further conversions from those tranches.The SEPA remains in place through December 20, 2026, allowing the company to sell up to an additional $10 million of common stock to Yorkville, subject to customary conditions. Management said the payoff strengthens the balance sheet and supports plans to initiate a Phase 1/2 trial of CYWC628 in early 2026, and to prepare IND submissions for CYPS317 and CYMS101.

#FBLG FibroBiologics Announces Payoff of Outstanding Debt

www.stocktitan.net/news/FBLG/fibro-biologic...

#FBLG FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

www.stocktitan.net/news/FBLG/fibro-biologic...

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and

#FBLG FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

www.stocktitan.net/news/FBLG/fibro-biologic...

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules FibroBiologics (Nasdaq: FBLG) announced a registered direct offering and concurrent private placement expected to close on or about November 19, 2025. The company agreed to sell 3,540,000 shares and pre-funded warrants to purchase 8,570,203 shares at $0.3303 per share/pre-funded warrant, with aggregate gross proceeds of approximately $4.0 million. Payment will be made in sovereign .9999 fine gold coins, which the company intends to liquidate to U.S. dollars. In the concurrent private placement, the company will issue unregistered warrants to purchase up to 12,110,203 shares at $0.3303, exercisable subject to stockholder approval and expiring five years after such approval.The company intends to use net proceeds for general corporate purposes, including debt repayment.

#FBLG FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

www.stocktitan.net/news/FBLG/fibro-biologic...

#FBLG: Diabetic Foot Ulcer Trial of CYWC628 to Initiate in 1Q26… buff.ly/XnRPRDh

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update FibroBiologics (Nasdaq: FBLG) reported Q3 2025 corporate updates and nine‑month results on Oct 31, 2025. Key program milestones target a Phase 1/2 trial of fibroblast‑based spheroid CYWC628 in diabetic foot ulcers with a planned initiation in Q1 2026 and completion in Q3 2026. The company completed IND‑enabling work for a psoriasis program and advanced a bone marrow organoid platform, plus a patent filing on multipotent cells from fibroblasts.Financials: R&D rose to $6.6M (nine months) from $3.1M in 2024, G&A was $7.4M, net loss widened to $15.4M, and cash totaled $4.9M at Sept 30, 2025. Manufacturing runs and cGMP completion targeted by end‑2025. The company implemented cost reductions and plans IND submissions for psoriasis and multiple sclerosis programs.

#FBLG FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/FBLG/fibro-biologic...

Breakthrough in Chronic Disease Treatment: FibroBiologics' 270+ Patents Show Fibroblasts Beat Stem Cells Biotech firm FibroBiologics reveals fibroblast cells' advantages over stem cells for chronic diseases, backed by 270+ patents. Shows faster proliferation, better sourcing, enhanced immune modulation.

#FBLG FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

www.stocktitan.net/news/FBLG/fibro-biologic...

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment FibroBiologics (NASDAQ:FBLG) has announced positive IND-enabling updates for its psoriasis treatment program using human dermal fibroblast (HDF) spheroids. The company reported that a single administration of HDF spheroids matched the efficacy of multiple doses of an anti-IL-23 monoclonal antibody in an acute psoriasis model, while also significantly reducing disease recurrence in a chronic-relapse model.The biotechnology company, which holds over 270 patents issued and pending, is advancing its research through pilot studies focused on repeated dosing regimens, cytokine profiling, and histopathological assessments. The treatment targets psoriasis, an autoimmune condition affecting more than 8 million adults in the United States, with potential to address the broader chronic inflammatory disease market.

#FBLG FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

www.stocktitan.net/news/FBLG/fibro-biologic...

#FBLG: Advancing Bone Marrow Organoid Platform for Cancer and Immune-Related Therapies… buff.ly/cEBFK7e

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies FibroBiologics (NASDAQ:FBLG) has announced significant progress in its Bone Marrow Organoid platform technology, showing promising potential for treating hematopoietic cancers and immune-related conditions. The company's pre-IND animal trials demonstrated that transplantation of these organoids significantly reduced tumor size in xenografted melanoma mouse models.Key technological advantages include efficient ex vivo gene editing capabilities and the ability to cryopreserve the organoids for scalable treatment options. The platform shows potential for regenerating immune cell types, addressing age-related immune decline, and restoring immune function in compromised patients. Additionally, the technology could enable in-vivo generation of advanced cell therapies like CAR-T and CAR-NK cells directly within patients.

#FBLG FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

www.stocktitan.net/news/FBLG/fibro-biologic...

#FBLG: Closes Third Tranche of $5M… buff.ly/uQ7TUwr

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications FibroBiologics (NASDAQ: FBLG) has filed a patent application with the USPTO for methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. The biotechnology company, which holds 275+ patents, focuses on developing therapeutics using fibroblasts and fibroblast-derived materials.The innovation enables the generation of stable multipotent cells directly from donor-derived fibroblasts, which can differentiate into various cell types including chondrocytes, osteocytes, hepatocytes, and cardiomyocytes. According to Chief Scientific Officer Hamid Khoja, this method allows for obtaining larger quantities of stable and scalable multipotent cells, with enhanced ability to form 3D spheroid structures.

#FBLG FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

www.stocktitan.net/news/FBLG/fibro-biologic...

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank FibroBiologics (NASDAQ: FBLG) has achieved a significant milestone in its cartilage repair program by confirming that CYWC628 spheroids from its existing master cell bank can be differentiated into chondrocytes for cartilage formation. This breakthrough enables the company to manufacture CybroCell™, its investigational cell therapy for degenerative disc disease (DDD).The development allows FibroBiologics to proceed with amending its FDA IND clearance for the planned Phase I clinical trial for DDD. The company's ability to use the existing master cell bank is expected to streamline manufacturing, reduce development time, and lower associated costs. This advancement demonstrates the potential versatility of FibroBiologics' fibroblast-based platform to support multiple therapeutic indications from a common cell source.

#FBLG FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

www.stocktitan.net/news/FBLG/fibro-biologic...

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing FibroBiologics (NASDAQ: FBLG) has successfully closed the third $5 million tranche of its previously announced $25 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors. This represents the final portion of the initial $15 million commitment structured through convertible promissory notes. The company has the potential to sell an additional $10 million in common stock to Yorkville, subject to conditions. FibroBiologics, a clinical-stage biotech company with 275+ patents, plans to use the proceeds for general corporate purposes, including funding R&D programs and supporting an upcoming Phase 1/2 diabetic foot ulcer clinical trial scheduled for the second half of 2025.

#FBLG FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

www.stocktitan.net/news/FBLG/fibro-biologic...

#FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis… buff.ly/4PThcBo

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting FibroBiologics (Nasdaq: FBLG) presented research findings at the Society for Investigative Dermatology Annual Meeting in San Diego. Dr. Chuo Fang delivered a poster presentation titled "Immunomodulatory Potential of Human Dermal Fibroblast Spheroids in Psoriasis Therapy" on May 9, 2025. The research showcased the potential of human dermal fibroblast (HDF) spheroids to reduce psoriasis severity in preclinical models. Chief Scientific Officer Dr. Hamid Khoja highlighted that their fibroblast-based candidate could offer a durable therapeutic option with unique immunomodulatory mechanisms, potentially providing sustained remission, reduced relapse, and fewer adverse side effects. FibroBiologics, a clinical-stage biotech company, holds 240+ patents/pending patents across various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer.

#FBLG FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

www.stocktitan.net/news/FBLG/fibro-biologic...

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update FibroBiologics (NASDAQ: FBLG) reported its Q1 2025 financial results and corporate updates. The company plans to initiate a Phase 1/2 clinical trial for its fibroblast-based spheroids product CYWC628 for diabetic foot ulcers in Q3 2025. Key achievements include completing a proprietary master cell bank, opening a new Houston laboratory, and demonstrating successful remyelination in neurodegenerative disease research. Financial results showed R&D expenses of $1.8 million (up from $1.0M in Q1 2024), G&A expenses of $2.8 million (up from $2.5M), and a reduced net loss of $5.0 million (down from $8.5M). The company ended Q1 2025 with $8.7 million in cash and cash equivalents.

#FBLG FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/FBLG/fibro-biologic...

OTC Markets Hosts Virtual Investor Presentation with Pete O'Heeron, CEO & Chairman of FibroBiologics, Inc. #FBLG, with David Bautz, PhD, Senior Analyst at Zacks SCR buff.ly/g0SPJj2

FibroBiologics Supercharges R&D with Massive New Lab Launch: In-House Manufacturing Next New 10,000 sq ft Houston facility enables in-house manufacturing and expanded research pipeline. 240+ patents support breakthrough fibroblast therapeutics development.

#FBLG FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

www.stocktitan.net/news/FBLG/fibro-biologic...

#FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25… buff.ly/ZA5QoPN